TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ).
CARsgen Therapeutics Holdings Ltd. has announced a share repurchase plan approved by its board of directors, allowing the company to buy back up to 1% of its total issued shares in the open market over 150 trading days starting May 8, 2025. The repurchase will be funded through non-IPO raised funds, including business development income and interest income, and aims to enhance shareholder value, although the exact timing and quantity of repurchases remain at the board’s discretion.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biopharmaceutical company focused on the development and commercialization of innovative CAR-T cell therapies. The company operates within the biotechnology industry, primarily targeting cancer treatment with a focus on advancing cell therapy solutions.
Average Trading Volume: 5,906,465
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.67B
For an in-depth examination of 2171 stock, go to TipRanks’ Stock Analysis page.